Regulation of mammalian iron homeostasis by iron and transferrin

铁和转铁蛋白对哺乳动物铁稳态的调节

基本信息

  • 批准号:
    8581642
  • 负责人:
  • 金额:
    $ 24.03万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-01 至 2015-11-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY (See instructions); As iron (Fe)-related disorders are prevalent world-wide, understanding Fe homeostasis is critical to understanding human health. Fe homeostasis is regulated by hepcidin, a largely liver-derived peptide that inhibits dietary Fe absorption and macrophage Fe recycling. Hepcidin expression Is inhibited and stimulated respectively by increased erythropoietic drive and Fe overload. The first objective of this K99/R00 application was to determine the effect of transferrin (TF) on hepcidin expression in vivo. This objective has been completed. Studies during the K99 phase demonstrated that TF, an abundant serum metal-binding protein essential for Fe delivery to bone marrow for erythropoiesis, regulates hepcidin expression dependently and Independently of TF's role In erythropoiesis. These studies also demonstrated that TF Is essential for the stimulation of hepcidin expression by Fe overload; this stimulation is a likely target ofthe unidentified factor that mediates suppression of hepcidin expression by increased erythropoietic drive. The second objective of this K99/R00 application, to be completed during the ROO phase, is to identify commonalities and divergences between cellular manganese (Mn) and Fe homeostasis as a means to further dissect Fe homeostasis. I will identify the means by which TF saturated with Fe, Mn and other metals similarly and differentially regulate hepatocyte gene expression and determine if TF plays a role In cellular Fe and Mn efflux. The third objective, also to be completed during the ROO phase, is to identify novel factors required for cellular metal homeostasis. As high Mn levels are toxic to many cell lines, I will alter cellular gene expression with shRNA and cDNA libraries, select for cells resistant to high Mn levels and Identify mutant lines of interest by 54Mn and 55Fe transport assays. From these two objectives, I will establish an Independent focus divergent from my mentor's, the role of Iron in hematologic disorders. This proposal reflects the overall trend in my research the study of mammalian metal homeostasis and its relation to human health and disease¿and will lead to a paradigm of metal homeostasis from which novel treatments for metal-related disorders can be designed.
项目总结(见说明); 由于铁(Fe)相关的疾病在世界范围内普遍存在,了解铁的动态平衡对于了解人类健康至关重要。铁的动态平衡是由海普西丁调节的,海普西丁是一种主要来自肝脏的多肽,它抑制饮食中铁的吸收和巨噬细胞铁的循环。红细胞生成驱动力增加和铁超载分别抑制和刺激了海普西丁的表达。本K99/R00应用的第一个目的是确定转铁蛋白(Tf)对体内表达的海普西丁的影响。这一目标已经完成。K99期的研究表明,Tf是一种丰富的血清金属结合蛋白,是铁转运到骨髓中促进红细胞生成所必需的,它依赖于和不依赖于Tf在红细胞生成中的作用来调节海普西丁的表达。这些研究还表明,Tf对于铁超载刺激海普西丁的表达是必不可少的;这种刺激可能是通过增加红细胞生成动力而抑制海普西丁表达的不明因子的一个靶点。这项K99/R00应用的第二个目标将在Roo阶段完成,目的是识别细胞锰(Mn)和铁稳态之间的共性和差异,以此作为进一步剖析铁稳态的手段。我将确定铁、锰和其他金属饱和的转铁蛋白的途径,以及差异调节肝细胞基因表达的方式,并确定转铁蛋白是否在细胞铁和锰的外流中发挥作用。第三个目标,也将在Roo阶段完成,是确定细胞金属动态平衡所需的新因素。由于高锰对许多细胞系有毒害作用,我将利用shRNA和cDNA文库改变细胞的基因表达,筛选耐高锰的细胞,并通过54MN和55Fe转运试验鉴定感兴趣的突变系。从这两个目标出发,我将建立一个有别于我导师的独立焦点,即铁在血液疾病中的作用。这一建议反映了我在研究哺乳动物金属动态平衡及其与人类健康和疾病的关系方面的总体趋势,并将导致金属动态平衡的范例,从中可以设计出金属相关疾病的新治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Thomas Benedict Bartnikas其他文献

Thomas Benedict Bartnikas的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Thomas Benedict Bartnikas', 18)}}的其他基金

Molecular Basis of Mammalian Manganese Homeostasis
哺乳动物锰稳态的分子基础
  • 批准号:
    10338149
  • 财政年份:
    2016
  • 资助金额:
    $ 24.03万
  • 项目类别:
Molecular Basis of Mammalian Manganese Homeostasis
哺乳动物锰稳态的分子基础
  • 批准号:
    9355175
  • 财政年份:
    2016
  • 资助金额:
    $ 24.03万
  • 项目类别:
Molecular Basis of Mammalian Manganese Homeostasis
哺乳动物锰稳态的分子基础
  • 批准号:
    10581434
  • 财政年份:
    2016
  • 资助金额:
    $ 24.03万
  • 项目类别:
Regulation of mammalian iron homeostasis by iron and transferrin
铁和转铁蛋白对哺乳动物铁稳态的调节
  • 批准号:
    8532426
  • 财政年份:
    2012
  • 资助金额:
    $ 24.03万
  • 项目类别:
Regulation of mammalian iron homeostasis by iron and transferrin
铁和转铁蛋白对哺乳动物铁稳态的调节
  • 批准号:
    7707314
  • 财政年份:
    2009
  • 资助金额:
    $ 24.03万
  • 项目类别:
Alpert Medical School Summer Research Program
阿尔珀特医学院暑期研究计划
  • 批准号:
    10386809
  • 财政年份:
    2009
  • 资助金额:
    $ 24.03万
  • 项目类别:
Alpert Medical School Summer Research Program
阿尔珀特医学院暑期研究计划
  • 批准号:
    10600999
  • 财政年份:
    2009
  • 资助金额:
    $ 24.03万
  • 项目类别:

相似国自然基金

基于构建骨骼类器官模型探究Fanconi anemia信号通路调控电刺激诱导神经化成骨过程的机制研究
  • 批准号:
    82302715
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
FANCM蛋白在传统Fanconi anemia通路以外对保护基因组稳定性的功能
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
范可尼贫血(Fanconi Anemia)基因FANCM在复制后修复中的作用及FA癌症抑制通路的机制研究
  • 批准号:
    31200592
  • 批准年份:
    2012
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Investigation of crosstalk between Fanconi Anemia pathway and ATM for novel therapeutic strategies of chemoresistant ALT-positive high-risk neuroblastoma
范可尼贫血通路与 ATM 之间的串扰研究,用于化疗耐药 ALT 阳性高危神经母细胞瘤的新治疗策略
  • 批准号:
    24K10442
  • 财政年份:
    2024
  • 资助金额:
    $ 24.03万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Immune escape mechanisms in BCOR/BCORL1 mutant hematopoietic stem cells from patients with aplastic anemia
再生障碍性贫血患者 BCOR/BCORL1 突变型造血干细胞的免疫逃逸机制
  • 批准号:
    23K15297
  • 财政年份:
    2023
  • 资助金额:
    $ 24.03万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Fanconi anemia経路に着目したiPS細胞における高レベル複製ストレスの原因解明
阐明 iPS 细胞中高水平复制应激的原因,重点关注范可尼贫血途径
  • 批准号:
    23K14452
  • 财政年份:
    2023
  • 资助金额:
    $ 24.03万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Analysis of the mechanism of hemolytic anemia in canine babesiosis and development of novel therapeutic measures
犬巴贝斯虫病溶血性贫血机制分析及新治疗措施开发
  • 批准号:
    23KJ0074
  • 财政年份:
    2023
  • 资助金额:
    $ 24.03万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Mobile phone-based screening for anemia in young children in western Kenya
基于手机的肯尼亚西部幼儿贫血筛查
  • 批准号:
    10752968
  • 财政年份:
    2023
  • 资助金额:
    $ 24.03万
  • 项目类别:
Brain blood flow, oxygenation, and cognition in adult onset iron deficiency anemia
成人缺铁性贫血的脑血流量、氧合和认知
  • 批准号:
    10735765
  • 财政年份:
    2023
  • 资助金额:
    $ 24.03万
  • 项目类别:
Chromatin State Alterations in Fanconi Anemia Hematologic Disease and Bone Marrow Failure
范可尼贫血血液疾病和骨髓衰竭中的染色质状态改变
  • 批准号:
    10735366
  • 财政年份:
    2023
  • 资助金额:
    $ 24.03万
  • 项目类别:
Accuracy and Feasibility of Non-Invasive Anemia Screening Assistant (ASIST) Device in Resource-Limited Settings
资源有限环境中非侵入性贫血筛查辅助 (ASIST) 设备的准确性和可行性
  • 批准号:
    10575222
  • 财政年份:
    2023
  • 资助金额:
    $ 24.03万
  • 项目类别:
Liver-Gut Axis in Neonatal Anemia and Its Role in RBC Transfusion Associated Gut Injury
新生儿贫血中的肝肠轴及其在红细胞输注相关肠道损伤中的作用
  • 批准号:
    10583807
  • 财政年份:
    2023
  • 资助金额:
    $ 24.03万
  • 项目类别:
A Sample-to-Answer Point-of-Care Diagnostic for Recently Transfused Sickle Cell Anemia Patients in Low Resource Settings
针对资源匮乏地区最近输血的镰状细胞性贫血患者的从样本到答案的护理点诊断
  • 批准号:
    10564553
  • 财政年份:
    2023
  • 资助金额:
    $ 24.03万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了